NSE:CAPLIPOINT's Gross Margin % is ranked better than 69.52% of 935
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs NSE:CAPLIPOINT: 60.42
Caplin Point Laboratories had a gross margin of 59.18% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Caplin Point Laboratories (NSE:CAPLIPOINT) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Caplin Point Laboratories had a gross margin of 59.18% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Caplin Point Laboratories Gross Margin % Related Terms
Caplin Point Laboratories Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CAPLIPOINT vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caplin Point Laboratories Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Caplin Point Laboratories's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Caplin Point Laboratories (NSE:CAPLIPOINT) has a Gross Margin % of 59.18% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Caplin Point Laboratories and its competitors. This is near median its historical median of 54.55. Over the past decade, Caplin Point Laboratories' Gross Margin % has ranged from 50.68 to 60.42. According to the industry distribution chart, Caplin Point Laboratories ranks #285 out of 935 companies in the Drug Manufacturers industry, placing it in the top 30.5%.
Is Caplin Point Laboratories' Gross Margin % too high?
Caplin Point Laboratories' current Gross Margin % of 59.18% is near median its 10-year median of 54.55. Over the past 10 years, this metric has ranged from a low of 50.68 to a high of 60.42. The Drug Manufacturers industry median Gross Margin % is 48.54. Caplin Point Laboratories' value of 59.18% is 21.9% above this industry median. Based on the distribution chart, Caplin Point Laboratories ranks #285 out of 935 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Caplin Point Laboratories has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caplin Point Laboratories' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Caplin Point Laboratories ranks #285 out of 935 companies for Gross Margin %. This puts Caplin Point Laboratories in the upper half of its industry. The industry median Gross Margin % is 48.54. Caplin Point Laboratories' value of 59.18% is 21.9% above this benchmark. Historically, Caplin Point Laboratories' own Gross Margin % has ranged from 50.68 to 60.42 over the past decade. While the company's 10-year median is 54.55 vs. the industry median of 48.54, Caplin Point Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caplin Point Laboratories's current Gross Margin % of 59.18% is 21.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Caplin Point Laboratories and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caplin Point Laboratories's current Gross Margin % is 59.18%, which is near median its own 10-year median of 54.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caplin Point Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Caplin Point Laboratories (NSE:CAPLIPOINT) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,073.29, compared to a current price of ₹2,557.90 — trading 23.4% above its estimated fair value. The current Gross Margin % is 59.18%, which is near median its 10-year median of 54.55 and 21.9% above the Drug Manufacturers industry median of 48.54. Caplin Point Laboratories' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Caplin Point Laboratories (NSE:CAPLIPOINT), the current Gross Margin % is 59.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caplin Point Laboratories (NSE:CAPLIPOINT) Overvalued in 2026?
Based on GuruFocus' analysis, Caplin Point Laboratories stock appears to be overvalued.
The current stock price of ₹2,557.90 is trading 23.4% above its estimated GF Value™ of ₹2,073.29.
GuruFocus considers Caplin Point Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:CAPLIPOINT:
Gross Margin %: 59.18% (near median its 10-year median of 54.55)
GF Value™: ₹2,073.29 vs. price of ₹2,557.90 (23.4% above fair value)
Industry Position: 21.9% above the Drug Manufacturers median (#285 of 935)
No single metric tells the full story. See the NSE:CAPLIPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
89GF Score
Get the complete analysis for NSE:CAPLIPOINT
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CAPLIPOINT has been successfully added to your 
